Genexine Gets Green Light For Stem Cell Cancer Trial
This article was originally published in PharmAsia News
Executive Summary
South Korean biotech firm Genexine’s R&D pipeline is progressing, with most of its therapies currently in Phase II clinical trials at home and abroad, and a new green light from domestic authorities to conduct a trial with a novel anticancer stem cell and gene therapy.
You may also be interested in...
Merck Marches Keytruda Into Next Wave Of Indications
ASCO is jumping off point as the company looks beyond melanoma and lung cancer to the next wave of potential cancer indications for its PD-1 inhibitor Keytruda, initiating pivotal trials in head & neck cancer and colorectal cancer.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.